A study to find the key messages that women with breast or ovarian cancer need about BRCA gene changes

Cancer type:

Breast cancer
Ovarian cancer





This study was for women with breast or ovarian cancer who have a change in a gene called BRCA1 or BRCA2. It was specifically for women who were the first in their family to be told they had the gene change.

More about this trial

Changes to genes are called mutations. Women with a BRCA1 or BRCA2 gene mutation have an increased risk of getting breast cancer and ovarian cancer.

If a woman is found to have a BRCA1 or BRCA2 gene mutation, genetic testing might also then be discussed with relatives. But there is no agreement about the information that women with a BRCA gene mutation should have.

An increasing number of people are being referred to cancer genetic services. As the demand for this service is rising, it is likely that genetic testing will take place in cancer (oncology) clinics, rather than specialist genetic clinics. So it is important to work out the key messages that women should have and when.

The information and advice that women get may affect the decisions they make about managing their own cancer risk. It could also have an impact on how they talk to other family members about this.

In this study, researchers asked women with cancer and a BRCA gene mutation to look at the information normally given to women in their situation. They also asked the same number of health professionals to look at this information.

The researchers wanted to find out:

  • what information these women needed
  • the best time to have this information

Summary of results

The study team were able to identify a number of key messages that were agreed on by both women with a BRCA gene mutation and the health professionals.

Of the 16 women with a BRCA gene mutation who took part:

  • 9 had breast cancer
  • 3 had ovarian cancer
  • 4 had both breast and ovarian cancer

In this group 5 of the women had the BRCA 1 mutation and 11 women had the BRCA 2 mutation.

The 16 health professionals that took part in the study included:

  • Clinical geneticists and genetic counsellors
  • Clinical nurse specialists
  • Cancer consultants, some of who specialised in gynaecological cancers, such as womb and ovarian cancers
  • Breast surgeons

The women with the BRCA mutations and the health professionals were asked to fill out some questionnaires which included:

  • an explanation of the purpose of the study
  • a definition of a key message
  • a list of information messages

The messages were information about BRCA gene mutations normally given to women with breast or ovarian cancer.

Both groups were asked to decide:

  • what they felt were the most important key messages
  • the best time for these messages to be communicated

The researchers looked at the replies. Any messages agreed as key messages were kept and those not seen as a key message were removed. All personal details were removed from the replies (anonymised) and the replies were then shared with other people taking part in the study.

Everyone was then asked if they agreed with the collected responses. This process happened up to 3 times.

30 key messages were agreed by both groups. 7 of these messages were agreed by over 9 out of 10 people (95%).

The 7 key messages

Results Diagram

The researchers say that these 7 key messages are not meant to be a definitive list. They recognise that some messages will not be relevant to all women and that some women will want more or less information. But they do think they can be a useful guide for health professionals talking to women with breast or ovarian cancer who are having genetic testing to look for with BRCA mutations.

The researchers found it reassuring that there was a high level of agreement amongst the health professionals. This was despite the fact that they came from various specialities and had different training.

The researchers also found a high level of agreement between women with a BRCA mutation and the health professionals. They thought this might reflect a general increase in awareness of the role of inherited genes in breast and ovarian cancer.

When to provide information
Both groups agreed that the best time to communicate these messages was before genetic testing and when a gene mutation was found.

The researchers concluded that the study results will help to develop new ways to provide information. This will be particularly useful as genetic testing becomes part of general cancer services.

The research team recognised that this study involved a small group of people and so it might not be possible to apply the results more widely.

They recognised that this study did not look at particular groups of people. For example, it didn’t look at the information needs of women who do not have cancer who have genetic testing. And it didn’t focus on the needs of men with a BRCA gene mutation.

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Ms Chris Jacobs

Supported by

Guy’s and St Thomas’ NHS Foundation Trust
NIHR Clinical Doctoral Research Fellowship
University College London (UCL)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think